Abstracts tagged "complement"

Abstract Number: 2401 • ACR Convergence 2024
A Novel Modeling Approach to Elucidate the Role of Autoantibodies in Complement Activation in SLE
David Pisetsky¹, Yuankang Zhao², Matthew Engelhard³, Amanda Eudy⁴, Philip Tedeschi⁵, Alex Verdone⁵, Megan Clowse⁶, Lisa Criscione-Schreiber², Jayanth Doss³, Mithu Maheswaranathan², Rebecca Sadun³, Kai Sun³ and Jennifer Rogers², ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham, ³Duke University, Durham, NC, ⁴Duke University, Raleigh, NC, ⁵Immunovant, Inc, New York, NY, ⁶Duke University, Chapel Hill, NC
Background/Purpose: In SLE, ANAs can promote pathogenesis by forming immune complexes (ICs) that activate complement. While antibodies to DNA (anti-DNA) are known to be associated…
Abstract Number: 0298 • ACR Convergence 2024
RAY121, a Novel Recycling Monoclonal Antibody Against Complement C1s: Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase 1a First in Human Clinical Trial in Healthy Adults
Miwa Haranaka¹, Akinori Yamada², Saki Takahashi², Keisuke Gotanda², Sonoko Nakano-Kanatani², Nana Uemura², Kensuke Ohnishi², Masanobu Nishidate², Ichio Ohnami² and Megumi Kai³, ¹Souseikai Hakata Clinic, Fukuoka, Japan, ²Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, ³Oita University, Oita, Japan
Background/Purpose: Complement C1s is one of the major components of the classical complement pathway (CP), and the abnormal activation of CP is implicated in several…
Abstract Number: 2478 • ACR Convergence 2024
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial
Christian Pagnoux¹, Antoine Neel², Sarah Bray³, Rachel E. Gurlin⁴, Darcy Trimpe⁵, David Jayne⁶ and Peter Merkel⁷, and ADVOCATE Study Group, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Department of Internal Medicine, CHU Nantes, Nantes, France, ³Amgen Ltd, Cambridge, United Kingdom, ⁴Amgen Inc., Mountain View, CA, ⁵Amgen Inc., Thousand Oaks, CA, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are subtypes of ANCA-associated vasculitis that frequently involve the kidneys. However, a subset of patients with…
Abstract Number: 0461 • ACR Convergence 2024
Complete Description of the Three Pathways of the Complement System in a Series of 430 Patients with Rheumatoid Arthritis
ivan Ferraz-Amaro¹, Maria Garcia-Gonzalez², Fuensanta Gomez-Bernal³, Juan Carlos Quevedo-Abeledo⁴ and Miguel Angel Gonzalez-Gay⁵, ¹Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ²Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, ³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁴Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, ⁵University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain
Background/Purpose: The complement (C) system has been implicated in the etiopathogenesis of rheumatoid arthritis (RA). We aimed to examine the correlation between an in-depth evaluation…
Abstract Number: 2480 • ACR Convergence 2024
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis and Ear, Nose, or Throat Involvement in a Phase 3 Trial
Robert Spiera¹, Robert Lebovics², Sarah Bray³, Rachel E. Gurlin⁴, David Jayne⁵ and Peter Merkel⁶, and ADVOCATE Study Group, ¹Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ²Hackensack Meridian University Health System, Hackensack, NJ, ³Amgen Ltd, Cambridge, United Kingdom, ⁴Amgen Inc., Mountain View, CA, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: In the phase 3 ADVOCATE trial, 45.2% and 42.1% of patients in the avacopan and prednisone taper groups, respectively, had active ear, nose, or…
Abstract Number: 0471 • ACR Convergence 2024
Understanding the Role of the Complement System in Insulin Resistance and Metabolic Syndrome in Patients with Rheumatoid Arthritis
Jose Viotti-Serra¹, Maria Garcia-Gonzalez², Fuensanta Gomez-Bernal¹, Juan Carlos Quevedo-Abeledo³, Miguel Angel Gonzalez-Gay⁴ and ivan Ferraz-Amaro⁵, ¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ²Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain
Background/Purpose: The complement (C) system has been associated with the etiopathogenesis of rheumatoid arthritis (RA). Insulin resistance (IR) and metabolic syndrome are prevalent among RA…
Abstract Number: 2483 • ACR Convergence 2024
Efficacy and Safety of Avacopan over 12 Months in Japanese Patients with MPA/GPA: A Single-center Study
Yusuke Ushio¹, Hiromi Shimada², taichi miyagi³, Koichi Sugihara⁴, Mao Mizusaki⁵, Rina Mino⁵, Hayamasa yamaguchi⁵, Naoto Manabe⁵, Shusaku Nakashima² and Hiroaki Dobashi², ¹Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, ²Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, kidagun, Japan, ⁴Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa Prefecture, Japan, ⁵Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: Avacopan, an oral C5a receptor inhibitor, was demonstrated to be an alternative to glucocorticoids (GC) in the treatment of microscopic polyangiitis (MPA)/granulomatosis with polyangiitis…
Abstract Number: 0497 • ACR Convergence 2024
Relationship Between the Complement System and Subclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis
Adrián Quevedo-Rodríguez¹, Marta Hernández-Díaz², Dara Rodríguez-González2², Fuensanta Gomez-Bernal³, Juan Carlos Quevedo-Abeledo⁴, Agustín F González-Rivero², Elena González López⁵, gonzalo Ocejo-Viñals⁵, Miguel Angel Gonzalez-Gay⁶ and ivan Ferraz-Amaro⁷, ¹Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²Hospital Universitario de Canarias, SANTA CRUZ DE TENERIFE, Spain, ³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁴Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, ⁵Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, ⁶University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) events and CV mortality. Carotid subclinical atherosclerosis is independently associated with incident…
Abstract Number: 2488 • ACR Convergence 2024
Patient Characteristics and Treatment Patterns Before and After Initiation of Avacopan in the United States: An Early View Based on a Claims Database Analysis
Sushmitha Inguva¹, Pallavi Rane¹, Darcy Trimpe¹, Sam Oh¹, Jasjit Multani², Hsiu-Ching Chang², Marie Yasuda², Chi-Chang Chen², Duvuru Geetha³, Peter Merkel⁴ and Zachary Wallace⁵, ¹Amgen Inc., Thousand Oaks, CA, ²IQVIA, Wayne, PA, ³Johns Hopkins University, Baltimore, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Massachusetts General Hospital, Newton, MA
Background/Purpose: The United States (US) Food and Drug Administration approved avacopan to treat adults with severe active granulomatosis with polyangiitis or microscopic polyangiitis in October…
Abstract Number: 0556 • ACR Convergence 2023
Classical Complement Activation in Lupus Nephritis Correlates with Disease Biomarkers: Results from Two Observational Studies
Edmund Chang¹, Julian Low¹, Noosha Yousefpour¹, Min Bao¹, Jeannette Osterloh¹, Qing Chang¹, Dean Artis¹, Henk-Andre Kroon¹, Yaisa Andrews-Zwilling¹, Maria Dall'Era², Ted Yednock¹ and Ann Mongan¹, ¹Annexon Biosciences, Brisbane, CA, ²University of California San Francisco, San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is an autoantibody-mediated disease that can activate C1q and the classical complement pathway. Pathogenic anti-C1q antibodies (PACAs) are often present, amplifying…
Abstract Number: 0924 • ACR Convergence 2023
Distinct Cell-Bound Complement Activation Products Associate with Disease Activity and Immune Transcriptional Signatures in SLE
Gabriel Arguelles, Lynne Mitchell, Dennis Hourcade, John Atkinson, Elisha Roberson and Alfred Kim, Washington University School of Medicine, St. Louis, MO
Background/Purpose: Complement plays a central role in SLE, generating an array of bioactive soluble and cell-bound complement activation products (CB-CAPs) during disease activity. Data are…
Abstract Number: 0562 • ACR Convergence 2023
HDL-Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus
Ivan Ferraz Amaro¹, Maria García-González¹, Fuensanta Gómez-Bernal¹, Juan Carlos Quevedo-Abeledo², Yolanda Fernández-Cladera¹, Agustín F González-Rivero¹ and Miguel A Gonzalez-Gay³, ¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain, ³IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain
Background/Purpose: Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL) cholesterol to accept cholesterol from macrophages, has been linked to cardiovascular events. Systemic lupus…
Abstract Number: 1591 • ACR Convergence 2023
Complement Factor D/Adipsin Knockout Mice Demonstrate Disparate Pain and Structural Damage Phenotypes in Obesity-induced Post Traumatic Osteoarthritis
Kelsey Collins¹, Kristin Lenz², Arin Oestreich², Luke Springer², Antonina Akk², Huimin Yan², Xiaobo Wu², John Atkinson³, Christine Pham⁴ and Farshid Guilak⁴, ¹University of California San Francisco, San Francisco, CA, ²Washington University in St. Louis, St. Louis, MO, ³Washington University School of Medicine, St. Louis, MO, ⁴Washington University, St. Louis, MO
Background/Purpose: Osteoarthritis (OA) is the leading cause of musculoskeletal pain, which is a primary driver of care-seeking behavior. There is lack of mechanistic information detailing…
Abstract Number: 0565 • ACR Convergence 2023
Insulin Resistance and the Complement System Are Linked in Patients with Systemic Lupus Erythematosus
José María Viotti-Serra¹, Maria García-González¹, Fuensanta Gómez-Bernal¹, Juan Carlos Quevedo-Abeledo², Yolanda Fernández-Cladera¹, Agustín F González-Rivero¹, Miguel A Gonzalez-Gay³ and Ivan Ferraz Amaro¹, ¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain, ³IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) patients more commonly have insulin resistance (IR) than control subjects. Recent studies have revealed that the complement (C) system is…
Abstract Number: 1605 • ACR Convergence 2023
Complement Activation as a Marker of Thrombosis Risk in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Cecile Yelnik¹, Shruti Chaturvedi², Julien Labreuche¹, Xiang-Zuo Pan³, H Michael Belmont⁴, Kello Nina⁵, Paul R. Fortin⁶, D. Ware Branch⁷, Yu Zuo⁸, Rohan Willis⁹, Robert Brodsky¹⁰, Jane Salmon¹¹, Maria Laura Bertolaccini¹², Hannah Cohen¹³, Michelle Petri¹⁴, Doruk Erkan¹¹ and On Behalf Of APS ACTION¹⁵, ¹University of Lille, Lille, France, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³John Hopkins University, Baltimore, MD, ⁴NYU School of Medicine, New York, NY, ⁵Northwell Health, Brooklyn, NY, ⁶Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ⁷University of Utah, Salt Lake City, UT, ⁸University of Michigan, Ann Arbor, MI, ⁹University of Texas Medical Branch, Galveston, TX, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Hospital for Special Surgery, New York, NY, ¹²King's College London, London, United Kingdom, ¹³University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ¹⁵on behalf of APS ACTION, New York, NY
Background/Purpose: Recent studies implicate complement activation in the pathophysiology of antiphospholipid syndrome (APS), especially in patients with severe manifestations, such as catastrophic APS (CAPS). This…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].